drugset / Trial / NCT00843921
N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia
Phase 2/3
Unknown
52 enrolled
Mendel Tuchman
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is based on the hypothesis that a new drug N-carbamylglutamate (Carbaglu®) will enhance the ability of the liver to dispose of toxic ammonia which accumulates in several metabolic diseases including urea cycle disorders and organic acid disorders.
Timeline
- Start
- 2008-08
- Primary completion
- 2018-04-25
- Completion
- 2020-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-carbamylglutamate | Unknown | 100 mg/kg | — |
| Subject | N-carbamylglutamate | Unknown | 2200 mg/m2 | — |